Prev Arrow Stocks

Biogen Inc. ($BIIB) Stock Forecast: Up 5.3% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Biogen Inc.?

Biogen Inc. (BIIB) is a biotechnology company specializing in therapies for neurological and neurodegenerative diseases, and recently saw a significant uptick in market performance.

Why is Biogen Inc. going up?

BIIB stock is up 5.3% on May 31, 2024 14:26

  • BIIB stock rose following marketing authorization from the European Commission for Qalsody, a treatment for a rare genetic form of Amyotrophic Lateral Sclerosis (ALS).
  • The approval of Qalsody contributed to increased investor confidence in Biogen's product pipeline and potential revenue growth.
  • Despite a legal challenge in the form of a securities class action lawsuit, market sentiment was largely driven by the positive EU approval, leading to a bullish trend in BIIB stock.
  • This approval highlights Biogen's dedication to addressing medical needs and expanding its range of therapies with innovative solutions.

BIIB Price Chart

BIIB News

How To Invest: Using Shorter-Term Moving Averages To Trade Stocks

IBD has clear rules for buying and selling stocks. But what about holding? If your stock hasn't obviously fallen apart, triggering the 7% sell rule, the decision can be less clear cut. Sell too soon, and you could miss out on potential gains. Sell too late, and you can take a huge hit.

https://www.investors.com/how-to-invest/investors-corner/how-to-invest-10-day-moving-average/

News Article Image How To Invest: Using Shorter-Term Moving Averages To Trade Stocks

Biogen: EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis

WESTON (dpa-AFX) - Biogen Inc. (BIIB) said that the European Commission has granted marketing authorization under exceptional circumstances and maintained orphan designation for Qalsody (tofersen)…

https://www.finanznachrichten.de/nachrichten-2024-05/62371386-biogen-eu-approves-qalsody-to-treat-rare-genetic-form-of-amyotrophic-lateral-sclerosis-020.htm

News Article Image Biogen: EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”). Biogen investors have until July 22, 2024 Jetzt den vollständigen Artikel lesen

https://www.wallstreet-online.de/nachricht/18147653-glancy-prongay-murray-llp-a-leading-securities-fraud-law-firm-announces-the-filing-of-a-securities-class-action-on-behalf-of-biogen-inc-biib-investors

News Article Image Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors

European Commission grants marketing approval to Biogen’s ALS drug

(Reuters) -Biogen said on Thursday that the European Commission has granted marketing authorization under exceptional circumstances for its amyotrophi…

https://kfgo.com/2024/05/30/european-commission-grants-marketing-approval-to-biogens-als-drug/

News Article Image European Commission grants marketing approval to Biogen’s ALS drug

Biogen Inc.: Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen''s third rare disease therapy to be approved in …

https://www.finanznachrichten.de/nachrichten-2024-05/62370180-biogen-inc-biogen-receives-european-commission-approval-for-qalsody-tofersen-the-first-therapy-to-treat-a-rare-genetic-form-of-als-399.htm

News Article Image Biogen Inc.: Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Inc. Price History

31.04.2024 - BIIB Stock was up 5.3%

  • BIIB stock rose following marketing authorization from the European Commission for Qalsody, a treatment for a rare genetic form of Amyotrophic Lateral Sclerosis (ALS).
  • The approval of Qalsody contributed to increased investor confidence in Biogen's product pipeline and potential revenue growth.
  • Despite a legal challenge in the form of a securities class action lawsuit, market sentiment was largely driven by the positive EU approval, leading to a bullish trend in BIIB stock.
  • This approval highlights Biogen's dedication to addressing medical needs and expanding its range of therapies with innovative solutions.

15.04.2024 - BIIB Stock was up 5.2%

  • BIIB stock surged today due to the FDA granting fast-track designation for its Alzheimer's treatment developed in collaboration with Eisai.
  • Eisai initiated the rolling submission of a Biologics License Application (BLA) for the Alzheimer's therapy to the FDA, contributing to the positive market sentiment towards BIIB.
  • The advancements in BIIB's Alzheimer's treatment pipeline have increased investor confidence in the company's revenue prospects and competitive stance, resulting in a notable uptick in the stock's performance today.

25.03.2024 - BIIB Stock was down 1.9%

  • Biogen posted better-than-expected earnings in the first quarter, surpassing consensus on adjusted EPS but falling short on sales, especially in the multiple sclerosis segment.
  • Despite the optimistic earnings results, slow uptake of Biogen's Alzheimer's drug, Leqembi, stemming from doubts among medical professionals, has sparked concerns about future revenue growth.
  • Analysts have adjusted their projections for Biogen, upholding their outperform rating on the stock despite the recent revenue dip, reflecting a mixed sentiment within the market.
  • The notable downward movement in Biogen's stock today may be attributed to investors paying more attention to the decline in revenue and the challenges in adopting its key drugs rather than the positive earnings surprise.

29.01.2024 - BIIB Stock was down 1.7%

  • BIIB stock experienced a decline greater than the overall market, finishing at $221.74, reflecting a -0.98% drop from the previous day's closing price.
  • The Multiple Sclerosis market is witnessing advancements in innovative treatments, potentially affecting BIIB's competitive edge in this sector.
  • Ginkgo Bioworks' acquisition of Patch Biosciences to bolster genetic medicine capabilities might have diverted attention from BIIB among investors.
  • Ongoing legal investigations by Bragar Eagel & Squire, P.C. against Biogen Inc. could have contributed to the pessimistic sentiment surrounding the stock.

14.01.2024 - BIIB Stock was down 7.3%

  • Several factors contribute to today's bearish movement in BIIB:
  • 1. Disappointing Q4 earnings: Biogen's Q4 earnings fell below expectations, indicating strategic challenges. This has potentially decreased investor confidence, leading to selling pressure.
  • 2. Rating downgrade: A downgrade to Biogen's rating has further weakened investor sentiment and contributed to the bearish movement.
  • 3. Lack of positive news: While there have been mentions of Biogen's growth projections and cost-cutting measures, the absence of significant positive news or developments may have influenced the bearish market movement.
  • 4. Overall market volatility: The biotechnology sector has experienced significant volatility, which could have impacted Biogen's stock price and intensified the bearish movement.
  • In conclusion, the bearish movement in BIIB today can be attributed to disappointing earnings, a rating downgrade, lack of positive news, and the overall market volatility in the biotechnology sector.

14.01.2024 - BIIB Stock was down 7.3%

  • In Q4, Biogen's sales and adjusted EPS fell short of expectations, disappointing investors.
  • The decline in multiple sclerosis revenue also contributed to the bearish movement.
  • A downgrade in rating and the failure to meet consensus on sales and EPS may have eroded investor confidence.
  • The announcement of PRIMECAP Management increasing its stake in Biogen could offer some support, but it was insufficient to counter the overall bearish sentiment.

14.01.2024 - BIIB Stock was down 7.3%

  • The bearish movement in Biogen's stock today can be attributed to several factors:
  • 1. Disappointing Q4 2023 earnings: Biogen reported lower-than-expected sales and adjusted earnings per share for the fourth quarter of 2023. This underperformance in financial results could have contributed to the bearish sentiment among investors.
  • 2. Missed consensus estimates: Biogen's Q4 2023 sales and adjusted EPS fell short of market expectations, indicating potential concerns about the company's ability to meet growth targets. This disappointment may have led to a sell-off in the stock.
  • 3. Market reaction to earnings call: Despite projecting growth amid new product launches and cost cuts, Biogen's earnings call may not have provided enough reassurance to investors. The market may have reacted negatively to any uncertainties or concerns raised during the call.
  • 4. Overall market conditions: The broader market movement and sentiment can also influence Biogen's stock performance. If there were negative trends or concerns in the biotech sector or the overall market, it could have contributed to the bearish movement in Biogen's stock.
  • In summary, Biogen's bearish movement today can be attributed to disappointing Q4 2023 earnings, missed consensus estimates, market reaction to the earnings call, and potential influence from broader market conditions.

13.01.2024 - BIIB Stock was down 7.3%

  • Today's downturn in BIIB can be attributed to the following factors:
  • 1. Underwhelming Q4 2023 earnings: BIIB's fourth-quarter sales and adjusted earnings fell below expectations. This may have eroded investor confidence, resulting in selling pressure on the stock.
  • 2. Falling short of consensus estimates: The company's sales and adjusted EPS did not meet analysts' consensus estimates, indicating potential concerns about its financial performance. This could have prompted a negative sentiment among investors, contributing to the bearish movement.
  • 3. Decline in multiple sclerosis revenue: BIIB experienced an 8% decrease in multiple sclerosis revenue during Q4 2023. This decline in a significant revenue-generating segment may have raised concerns about the company's ability to sustain growth and profitability.
  • 4. Market volatility: The biotech stock market has exhibited volatility, with investors closely monitoring clinical trial outcomes and regulatory approvals. Any adverse news or uncertainty within the broader biotech sector may have influenced the bearish movement in BIIB.
  • Overall, factors such as disappointing earnings, missed consensus estimates, declining multiple sclerosis revenue, and market volatility likely account for the bearish movement in BIIB today.

13.01.2024 - BIIB Stock was down 7.5%

  • Biogen's Q4 2023 earnings call transcript and sales report revealed a decline in sales and adjusted EPS, falling short of expectations. This negative financial performance likely contributed to the downward movement in the stock.
  • The increase in PRIMECAP Management's investment in Biogen initially generated some positive sentiment, but it appears to have been overshadowed by the negative impact of the earnings report.
  • The stock's decline was further emphasized in several articles, with headlines highlighting the disappointment in Biogen's earnings and subsequent drop in stock price.
  • The bearish movement in Biogen's stock was driven by the overall market sentiment towards biotech stocks and the company's specific financial performance.

13.01.2024 - BIIB Stock was down 5.5%

  • The bearish movement in BIIB today can be attributed to disappointing earnings results and lower-than-expected sales. The key factors influencing the market movement are:
  • 1. Missed sales and earnings expectations: Biogen reported fourth-quarter sales of $2.39 billion, falling short of the consensus estimate. Additionally, adjusted EPS of $2.95, down 27%, missed the consensus. This underperformance likely contributed to the bearish sentiment.
  • 2. Multiple sclerosis revenue decline: Biogen's multiple sclerosis revenue of $1.17 billion decreased by 8%. Slowing demand for its multiple sclerosis treatments impacted the company's profitability and investor confidence.
  • 3. Costs related to Alzheimer's treatment: Biogen also faced costs associated with the closeout of an Alzheimer's treatment. These costs likely weighed on the company's profit margins and added to the negative sentiment surrounding the stock.
  • Overall, the disappointing earnings report and challenges in key revenue streams, coupled with the costs associated with the Alzheimer's treatment, contributed to the bearish market movement in BIIB today.

13.01.2024 - BIIB Stock was down 5.9%

  • The company reported lower earnings and revenues for the fourth quarter of 2023, resulting in a 6% year-over-year decline in total revenue. This financial performance negatively impacted the stock.
  • Both adjusted earnings per share and sales figures fell below analysts' expectations, further impacting investor sentiment towards the stock.
  • Disappointing sales projections for Biogen's Leqembi also added to the prevailing negative sentiment surrounding the company.
  • The overall market conditions, including weak Swiss inflation and a decline in US stocks during premarket trading, may have also influenced Biogen's bearish movement.

13.01.2024 - BIIB Stock was down 5.5%

  • The bearish movement in BIIB today can be attributed to the following factors:
  • 1. Earnings Miss: Biogen reported lower than expected adjusted earnings of $2.95 per share and $2.39 billion in fourth-quarter sales. This disappointment in financial performance likely contributed to the bearish movement.
  • 2. Aduhelm Exit Costs: Biogen incurred costs due to the exit of its Alzheimer's drug, Aduhelm, impacting its fourth-quarter profit. The market may have reacted negatively to the financial implications of this decision.
  • 3. Revenue Miss: Alongside the earnings miss, Biogen also fell short of consensus revenue estimates. This could have further fueled the bearish sentiment among investors.
  • 4. Market Reaction: The decline in Biogen's stock price was a result of the earnings and revenue misses. The market's response to these factors likely intensified the bearish movement.
  • Overall, the bearish movement in BIIB today can be attributed to the company's earnings and revenue misses, as well as the costs associated with the exit of Aduhelm.

08.10.2023 - BIIB Stock was down 5.9%

  • Biogen's stock experienced a strong bearish movement today.
  • The company cut its profit outlook due to higher merger and acquisition costs and expenses related to its Alzheimer's drug.
  • The Q3 2023 earnings report showed a slight increase in total revenue but a net loss for the company.
  • The market sentiment was also influenced by anticipation of Federal Reserve Chair Jerome Powell's speech on interest rates and the state of the economy.
  • Overall, Biogen's bearish movement can be attributed to the company's revised profit outlook and the broader market sentiment influenced by the Federal Reserve's stance on interest rates.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.